NASDAQ:AYTU
Aytu Biopharma, Inc.
Aytu Biopharma, Inc.'s revenue fell 13.3% in fiscal 2026 to $57.6M while operating margin fell to −14.4%. Free cash flow was $3.3M, 5.6% of revenue.Summary generated from Aytu Biopharma, Inc.'s SEC filings. Latest annual report filed Sep 22, 2026.
Key statistics
Fiscal 2026 from SEC filings. MethodologyRevenue (FY26)$57.6M
Revenue growth−13.3%
Revenue, 5-yr CAGR−2.6%
Gross margin64.0%
Operating margin−14.4%
Net margin−24.8%
ROIC−63.5%
Return on equity−52.6%
Debt / equity0.31
Free cash flow$3.3M
FCF margin5.6%
Share count changen/a
Financials
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | 97 | 107 | 65 | 66 | 58 |
| Operating income | −110 | −17 | −2 | −8 | −8 |
| Net income | −109 | −17 | −16 | −14 | −14 |
| Free cash flow | −29 | n/a | −2 | −2 | 3 |
Recent filings
- 10-KAnnual report for the fiscal year ended Jun 30, 2026
Sep 22, 2026 - 8-KResults of operations and financial condition
Sep 22, 2026 - 4Insider transaction report
Jul 30, 2026 - 4Insider transaction report
Jul 30, 2026 - 8-KTermination of a material agreement
Jun 25, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 13, 2026 - 8-KResults of operations and financial condition
May 13, 2026 - 8-KEntry into a material agreement
Apr 2, 2026